Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Giotrif identified as effective lung cancer treatment

Giotrif identified as effective lung cancer treatment

14th April 2016

Boehringer Ingelheim's cancer drug Giotrif (afatinib) has been found to reduce the risk of lung cancer progression and treatment failure.

A study published in The Lancet Oncology found that it significantly improved clinical outcomes compared to Iressa (gefitinib) in EGFR mutation-positive advanced non-small cell lung cancer.

This was achieved with compromising overall health-related quality of life, safety and tolerability

Scientists behind the study believe the results give oncologists who treat patients with EGFR mutation-positive lung cancer "important information for clinical practice".

Professor Keunchil Park, director of the Innovative Cancer Medicine Institute at Samsung Medical Center, Sungkyunkwan University School of Medicine, commented: "The key finding from this study suggests a significant difference in efficacy between afatinib and gefitinib across multiple endpoints and pre-defined patient subgroups.”

Dr Mehdi Shahidi of Boehringer Ingelheim added that the results are likely to guide future treatment practices in EGFR mutated NSCLC.ADNFCR-8000103-ID-801816569-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.